Doutor Nichires Holdings Co., Ltd. (3087) AI Stock Analysis

• Market Cap: ¥124.69B
• Dividend Yield: 2.09%
• Average Volume (3M): 126.76K
• Price to Earnings (P/E): 17.6
• Beta (1Y): 0.29
• Revenue Growth: 5.78%
• EPS Growth: 10.26%
• Country: JP
• Employees: 2,765
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Restaurants
• EPS (TTM): 43.35
• Shares Outstanding: 45,609,760
• 10 Day Avg. Volume: 95,670
• 30 Day Avg. Volume: 126,763
• PEG Ratio: 0.59
• Price to Book (P/B): 1.01
• Price to Sales (P/S): 0.70
• P/FCF Ratio: 16.14
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: ¥3,102.00 ▲(19.40% Upside)

Doutor Nichires Holdings Co., Ltd. receives a strong overall stock score driven primarily by its robust financial performance, including solid revenue growth and a strong balance sheet. Technical analysis presents mixed signals, with short-term weakness but long-term support, while valuation indicates the stock is fairly priced with a moderate dividend yield.

Positive Factors

Low leverage / strong balance sheet

Low debt and a solid equity ratio give the company durable financial flexibility to withstand sector downturns, invest in store upgrades or wholesale capacity, and pursue opportunistic M&A without jeopardizing liquidity or credit standing over the next 2–6 months.

Improving margins and profitability

Sustained margin improvement indicates effective cost controls and operational efficiency, which support higher cash generation and reinvestment. Improved EBIT/EBITDA margins create a structural buffer against commodity and labor cost pressure, aiding longer-term profitability.

Consistent positive operating cash flow

Reliable operating and free cash flow supports reinvestment in stores, wholesale growth, and shareholder returns. Strong cash conversion also reduces reliance on external financing and underpins sustainable capital allocation over multiple quarters.

Negative Factors

Concentration in retail foodservice footprint

A business concentrated in brick-and-mortar coffee shops remains exposed to structural shifts in foot traffic, urban consumption patterns, and fixed-cost pressures; persistent adverse trends could depress revenue per location and require sustained capex to adapt.

Moderate revenue growth rate

Mid-single-digit revenue growth suggests limited top-line expansion velocity versus higher-growth sectors; absent material new channels or product lines, slower revenue growth constrains scalability and reduces margin expansion potential over the medium term.

Reliance on franchising for expansion

While franchising lowers capital needs, it can dilute operational control and brand consistency, creating variability in customer experience and unit economics. Over time this can cap same-brand margin improvement and complicate execution of uniform quality or pricing strategies.

Doutor Nichires Holdings Co., Ltd. Business Overview & Revenue Model

Company Description

DOUTOR NICHIRES Holdings Co., Ltd. manages restaurants and cafes in Japan. It manufactures and sells bread and pastry products; roasts and sells coffee; and imports, exports, purchases, and sells food products. The company also engages in the manufacture and wholesale of confectionary products; operation of bakery shops; wholesale of coffee machines, etc.; wholesale of fruits and vegetables; processing and wholesale of meat; manufacture of hams, sausages, and bacons; manufacture and wholesale of dressing products; and import of coffee beans and tea. In addition, it designs, constructs, maintains, and cleans stores; and operates natural food stores. DOUTOR NICHIRES Holdings Co., Ltd. was founded in 2007 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Doutor Nichires Holdings generates revenue primarily through its coffee shop and restaurant operations, where it sells a variety of coffee drinks, light meals, and snacks. The company's revenue model includes direct sales from retail locations, where customers pay for products and services. Additionally, Doutor Nichires earns revenue from the wholesale distribution of coffee beans and related products to other businesses, including restaurants, hotels, and retail outlets. Partnerships with suppliers and distributors enhance its market reach and product availability. Furthermore, the company may benefit from franchise operations, allowing it to expand its brand presence with reduced capital investment. Seasonal promotions and marketing strategies also contribute to increasing sales during peak times.

Doutor Nichires Holdings Co., Ltd. Financial Statement Overview

Summary

Doutor Nichires Holdings Co., Ltd. exhibits a strong financial performance with solid revenue growth, improved profit margins, and robust cash flow metrics. The balance sheet is strong with low leverage, indicating prudent financial management and a positive outlook for continued success.

Income Statement

Doutor Nichires Holdings Co., Ltd. has demonstrated strong revenue growth over the past years, with a notable recovery from past losses. The company's gross and net profit margins have improved significantly in recent years, reflecting effective cost management and increased efficiency. The EBIT and EBITDA margins have also shown positive trends, indicating robust operational performance.

Balance Sheet

The company maintains a strong financial position with a low debt-to-equity ratio, reflecting prudent financial management and low leverage risk. The equity ratio indicates a solid capital structure with substantial shareholder equity backing the company's assets. The return on equity has improved, showcasing enhanced profitability and efficient use of equity capital.

Cash Flow

Doutor Nichires Holdings has consistently generated positive operating cash flows, which have supported its investment activities and capital expenditures. The free cash flow growth rate is strong, suggesting healthy cash generation and potential for reinvestment or shareholder returns. The operating cash flow to net income ratio reflects a robust cash conversion cycle.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	151.23B	148.82B	140.63B	126.86B	109.36B	96.14B
Gross Profit	90.45B	89.62B	84.19B	74.77B	64.31B	55.77B
EBITDA	13.82B	13.94B	11.72B	6.88B	7.63B	-4.40B
Net Income	6.58B	6.88B	5.49B	3.43B	1.22B	-10.98B
Balance Sheet
Total Assets	133.54B	134.23B	127.79B	121.04B	118.23B	115.25B
Cash, Cash Equivalents and Short-Term Investments	33.34B	38.99B	35.80B	32.22B	34.55B	26.31B
Total Debt	2.04B	2.11B	2.40B	1.71B	1.54B	1.31B
Total Liabilities	32.33B	29.88B	28.32B	24.75B	24.12B	21.25B
Stockholders Equity	100.86B	104.00B	99.15B	96.01B	93.86B	93.78B
Cash Flow
Free Cash Flow	0.00	6.49B	6.87B	-221.00M	10.22B	-8.06B
Operating Cash Flow	0.00	12.35B	11.79B	5.17B	14.64B	-2.88B
Investing Cash Flow	0.00	-6.23B	-4.90B	-5.59B	-4.93B	-5.95B
Financing Cash Flow	0.00	-2.93B	-3.37B	-1.98B	-1.50B	-2.15B

Doutor Nichires Holdings Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2598.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3087, the sentiment is Positive. The current price of 2598 is below the 20-day moving average (MA) of 2718.15, below the 50-day MA of 2621.04, and above the 200-day MA of 2588.51, indicating a bullish trend. The MACD of 63.70 indicates Negative momentum. The RSI at 70.55 is Negative, neither overbought nor oversold. The STOCH value of 57.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3087.

Doutor Nichires Holdings Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3087	70 Outperform	¥124.69B	17.59	―	2.09%	5.78%	10.26%
8153	70 Outperform	¥129.97B	30.95	―	0.70%	5.15%	47.13%
7630	66 Neutral	¥143.18B	50.66	―	1.71%	9.51%	6.29%
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
2695	58 Neutral	¥135.03B	37.53	―	0.63%	4.32%	11.78%
9887	57 Neutral	¥125.77B	46.67	―	0.37%	20.44%	13.71%
7412	41 Neutral	¥116.82B	165.73	―	―	-12.01%	―

Doutor Nichires Holdings Co., Ltd. Corporate Events

Doutor-Nichires Lifts Dividend Forecast as Earnings Recover Despite Cost Pressures

Doutor-Nichires Holdings has revised upward its dividend forecast for the fiscal year ending February 2026, citing steady sales growth and a recovery in performance in the second half of the year despite pressures from higher raw material costs and rising selling, general and administrative expenses. Maintaining its policy of linking shareholder returns to earnings with a payout ratio target of 30–40%, the company now plans a year-end dividend of ¥29 per share, up from a previous forecast of ¥27, bringing the projected annual dividend to ¥56, an increase of ¥6 from the prior year, signaling management’s confidence in the resilience of its earnings and commitment to enhancing shareholder returns.

The most recent analyst rating on (JP:3087) stock is a Hold with a Yen2688.00 price target. To see the full list of analyst forecasts on Doutor Nichires Holdings Co., Ltd. stock, see the JP:3087 Stock Forecast page.

DOUTOR·NICHIRES Posts Higher Sales but Flat Profits, Lifts Dividend and Keeps Outlook

DOUTOR·NICHIRES Holdings reported consolidated net sales of ¥119.7 billion for the nine months ended November 30, 2025, up 6.5% year on year, while operating profit was almost flat at ¥8.0 billion and profit attributable to owners of parent edged down 0.6% to ¥5.75 billion, indicating that higher sales did not fully translate into bottom-line growth. The company’s equity ratio remained solid at 76.1%, and it continues to return cash to shareholders, raising the interim dividend to ¥27 per share and forecasting a full-year dividend of ¥56, while maintaining its full-year outlook for fiscal 2026 with net sales of ¥154.5 billion and a double‑digit increase in operating profit, suggesting confidence in earnings resilience despite margin pressure and ongoing share buybacks that have reduced shares outstanding and increased treasury stock.

The most recent analyst rating on (JP:3087) stock is a Hold with a Yen2688.00 price target. To see the full list of analyst forecasts on Doutor Nichires Holdings Co., Ltd. stock, see the JP:3087 Stock Forecast page.